Coverage of the 73rd Scientific Sessions of the American Diabetes Association.

With the unveiling of the first FDA-approved system with the name "artificial pancreas," Medtronic will seek a new CMS code that would cover both the insulin pump and the continuous glucose monitoring parts of the process, according to the company.

With speculation about an artificial pancreas rising, the September edition of Evidenced-Based Diabetes Management looked at the three systems that were being considered by the FDA – including the threshold suspend technology Medtronic announced Friday – and asked the next questions: Assuming the technology is approved, will insurers pay for it? How will this potentially life-altering advance make its way into the hands of the persons with diabetes who need it most?

Bernard Zinman, MD, the director of the Leadership Sinai Centre for Diabetes and the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto in Canada, discusses the new therapies, SGLT-2 inhibitors, that are now approved in the United States and European Union. These drug therapies have shown clinical benefits in both type 1 and type 2 diabetes, and may also improve cardiovascular outcomes for patients with type 2 diabetes

Jaakko Tuomilehto, MD, PhD, a professor of public health at the University of Helsinki in Finland provides global epidemiological data for T1DM and discusses the World Health Organization's Diabetes Mondiale (DiaMond) study. He compares the rates of incidences of T1DM among well-developed, high-income countries to low- and middle-income nations and takes note of the epidemiological trends.

Jaakko Tuomilehto, MD, PhD, a professor of public het the University of Helsinki in Finland explains the association between a country's socioeconomic status and its epidemiology of type 1 diabetes (T1DM), shedding light on the various circumstances and factors that may contribute to the differences we see among other nations.